Medtronic plc

Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB

Orchestra BioMed (OBIO) announced an R&D Day on November 12, 2026, in New York City with a live webcast, covering AVIM Therapy and Virtue SAB clinical programs. Medtronic is Orchestra BioMed's strategic collaboration partner for developing and commercializing AVIM Therapy for uncontrolled hypertension in pacemaker-indicated patients. The event is a scheduling notice only — no new clinical data or financial results were disclosed; relevant for MDT only as context on its pacing-partnership pipeline.

•3d ago

How an Olympic Runner Found Relief From Fecal Incontinence

Medtronic published a compensated patient story featuring former Olympian Krishna Stanton, who describes relief from fecal incontinence using InterStim sacral neuromodulation therapy. Stanton received her first implant in 2007 and later transitioned to the newer InterStim X system, crediting the therapy and Medtronic support staff with helping her return to running; she set an age-group world marathon record in 2022. The release is brand-awareness content with no new financial results, clinical trial data, or regulatory developments.

•6d ago

Medtronic Named to TIME Best Inventions of 2026 List for Stealth AXiS™ surgical system and Corsano™* multi-parameter wearable

Medtronic's Stealth AXiS surgical system and the Corsano multi-parameter wearable were named to TIME's Best Inventions of 2026 list. Stealth AXiS integrates planning, navigation, and robotic-assisted execution in one platform within Medtronic's AiBLE ecosystem, supporting spinal, cranial, and ENT procedures. The Corsano wearable is manufactured by Corsano Health B.V. and distributed by Medtronic in the U.S. and Western Europe. The release is brand-recognition PR with no financial figures; commercial impact is not quantified.

•10d ago

Medtronic Completes Separation of MiniMed Group, Inc.

Medtronic completed the separation of MiniMed Group, which now trades independently on Nasdaq as MMED. Medtronic exchanged all of its remaining 252,813,348 MiniMed shares into its exchange offer, which was 5.4x oversubscribed, marking the split as final. Medtronic will now focus on its Cardiovascular, Neuroscience and Surgical portfolios, while MDT holders who tendered receive MiniMed shares in book-entry form.

•10d ago

Medtronic Announces Final Results of MiniMed Group, Inc. Exchange Offer

Medtronic announced final results of its exchange offer separating its remaining stake in MiniMed Group, which was oversubscribed and expired October 9, 2026. Medtronic will exchange its entire remaining interest — 252,813,348 MiniMed shares — for 55,032,401 Medtronic ordinary shares, with a final proration factor of 18.289133% applied to tendered shares other than odd-lot positions. After completion, Medtronic will retain no MiniMed shares, fully concluding the separation; roughly 297.5 million Medtronic shares were validly tendered versus 55.0 million accepted, signaling strong shareholder demand to exit MDT into MiniMed.

•11d ago

How Heart Monitoring and Ablation Helped One Father Overcome AFib

Medtronic published a patient story about Todd Repass Jr., whose atrial fibrillation was diagnosed and managed using the LINQ II insertable cardiac monitor and later treated with pulsed field ablation using the Sphere-9 catheter. The LINQ II, an insertable monitor about a third the size of a AAA battery, captured AFib episodes that external Holter monitors had missed, guiding doctors to recommend the ablation. More than a year after the procedure, Repass reports being AFib-free with continued device monitoring. The release is branded marketing content with no financial or clinical-trial data relevant to Medtronic's results.

•13d ago

Medtronic Announces Preliminary Results of MiniMed Group, Inc. Exchange Offer

Medtronic announced preliminary results of its split-off exchange offer for MiniMed Group: the offer was oversubscribed and Medtronic will exchange all 252,813,348 remaining MiniMed shares. Holders will receive 4.5939 MiniMed shares per Medtronic share accepted, with an estimated 18.3% of tendered shares exchanged on a pro rata basis; approximately 298 million Medtronic shares were validly tendered and 55,032,401 will be accepted. The final proration factor is expected October 14, 2026, after which Medtronic will retain no MiniMed stake, completing its separation of the diabetes business.

•13d ago

Medtronic Announces Final Exchange Ratio of 4.5939 in Split-Off of MiniMed Group, Inc.

Medtronic set the final exchange ratio at 4.5939 MiniMed shares per Medtronic ordinary share in its split-off exchange offer, which expires at midnight NYC time on Oct. 9, 2026. The offer covers up to 225,361,295 MiniMed shares, and if oversubscribed Medtronic intends to exchange all remaining interest — an additional 27,452,053 shares — without extending the offer period. Because the calculated ratio exceeded the 4.5939 upper limit, tendering shareholders face proration; Goldman Sachs and BofA Securities are dealer managers.

•18d ago

MDT: 425 · other

Medtronic filed a Rule 425 communication regarding an exchange offer in which it will offer up to 225,361,295 newly issued shares of MiniMed Group, Inc. common stock — currently owned by Medtronic — in exchange for shares of Medtronic common stock. This exchange offer is the key step in Medtronic's separation of its MiniMed diabetes business, allowing Medtronic shareholders to elect shares in the spun-off entity. A dedicated information-agent website maintained by DF King (dfking.com/MDTSeparation) has been established for offer details. The separation will create an independent publicly traded MiniMed company and reshape Medtronic's post-spin profile.

SEC 425•18d ago

Medtronic Impact Report Highlights More Than 82 Million Patients Served Worldwide in Fiscal Year 2026

Medtronic released its FY26 Impact Report, highlighting more than 82 million patients served worldwide and $2.9 billion invested in research and development. The report also notes more than 315 product approvals in major markets, including the December 2025 FDA clearance of the Hugo robotic-assisted surgery system, plus ESG metrics such as 65% renewable electricity sourcing and a 68% reduction in Scope 1 and 2 intensity versus the FY20 baseline. This is a corporate-responsibility disclosure with no new financial results or guidance; the impact on MDT's near-term investment case is negligible.

•19d ago

MDT: 425 · acquisition merger

Medtronic plc filed a Rule 425 communication disclosing that it maintains a website at dfking.com/MDTSeparation in connection with its planned separation of MiniMed Group, Inc. Under the exchange offer, Medtronic will offer up to an aggregate of 225,361,295 newly issued shares of MiniMed Group common stock, which are owned by Medtronic, in exchange for shares of Medtronic common stock. The filing is procedural in nature but signals progress on the MiniMed separation, a structural event that will directly affect MDT shareholders' ownership and the composition of the post-separation company.

SEC 425•20d ago

MDT: 425 · acquisition merger

Medtronic filed a Rule 425 communication regarding its offer to exchange up to 225,361,295 newly issued shares of MiniMed Group, Inc. common stock, which Medtronic owns, for shares of Medtronic common stock. The filing announces a dedicated website maintained by information agent DF King at dfking.com/MDTSeparation to support the separation transaction. The exchange offer is the mechanism for Medtronic's separation of its MiniMed diabetes business, and acceptance levels will determine how much Medtronic stock is retired in the split-off.

SEC 425•24d ago

Medtronic Named to Fortune 2026 'Change the World' List for Touch Surgery(TM) Ecosystem and Healthy Neighbor

Medtronic was named to the FORTUNE 2026 'Change the World' list for its Touch Surgery ecosystem and the Healthy Neighbor program run through Medtronic LABS. Touch Surgery now supports thousands of surgeons in 30+ countries, and the July 2026 launch of Touch Surgery Aide added AI-powered real-time support for robotic and laparoscopic procedures. The Healthy Neighbor program with Virtua Health in Camden, NJ reported that 74% of patients with uncontrolled hypertension and 69% with uncontrolled diabetes achieved meaningful improvement over two years.

•25d ago

MDT: 425 · acquisition merger

Medtronic filed a Rule 425 communication referencing its offer to exchange newly issued shares of MiniMed Group, Inc. common stock — up to 225,361,295 shares owned by Medtronic — for shares of Medtronic common stock. The exchange offer is part of Medtronic's separation of its MiniMed business, with investor information maintained at dfking.com/MDTSeparation. The transaction will reduce Medtronic's share count in exchange for distributing MiniMed equity, restructuring the company's perimeter and affecting shareholder positions.

SEC 425•27d ago

From Caregiver to Engineer

Medtronic's Spark Scholarship enabled Berkeley high school graduate Shawn Wei, who served as a young caregiver during his father's cancer illness, to study Mechanical Engineering at USC this fall. The profile highlights Medtronic's Spark program, which supports students with mentorship, career guidance, and industry connections beyond tuition. Applications for the next round of Medtronic Spark scholarships open Oct. 26; this is corporate brand storytelling with no financial impact.

•27d ago

MDT: 425 · acquisition merger

Medtronic filed a Rule 425 communication from Fidelity informing 401(k) plan participants of their option to participate in the exchange offer tied to the planned separation of MiniMed into an independent company. Under the offer, Medtronic is offering up to 225,361,295 MiniMed shares in exchange for tendered Medtronic shares at a 7% discount, delivering approximately $107.53 of MiniMed stock per $100 of Medtronic shares tendered, with an upper limit of 4.5939 MiniMed shares per Medtronic share and no lower limit. Plan participants must instruct Fidelity by October 5, 2026, four business days before the offer's October 9 expiration; the Plans will liquidate any MiniMed shares received and reinvest proceeds in target date funds. If the offer is not fully subscribed, non-participating holders may still receive MiniMed shares via distribution.

SEC 425•0mo ago

MDT: 425 · acquisition merger

Medtronic filed a Rule 425 communication referencing an offer to exchange up to 225,361,295 newly issued MiniMed Group, Inc. shares for shares of Medtronic common stock. The filing points to a website maintained by DF King (dfking.com/MDTSeparation) supporting the Medtronic separation process. The exchange is a key step in Medtronic's separation of its diabetes business into MiniMed Group, materially restructuring Medtronic's share base.

SEC 425•1mo ago

MDT: 425 · acquisition merger

Medtronic plc filed a Form 425 disclosing an informational website, maintained at dfking.com/MDTSeparation by D.F. King, established in connection with the planned separation of its MiniMed diabetes business. The notice confirms Medtronic's offer to exchange up to an aggregate of 225,361,295 newly issued shares of common stock of MiniMed Group, Inc. — shares currently owned by Medtronic — for shares of Medtronic common stock, with further detail described in a prospectus referenced but not included in this filing. This is a split-off-style exchange offer in which Medtronic shareholders can swap MDT shares for MiniMed Group shares as the diabetes unit separates from the parent; the filing itself is procedural and contains no exchange ratio, deadline, or proration terms.

SEC 425•1mo ago

MDT: 425 · acquisition merger

Medtronic plc filed a Form 425 on September 21, 2026, the form used for communications issued under Rule 425 in connection with a business combination transaction. The filing document is named for a MiniMed split-off, indicating it relates to the planned separation of Medtronic's diabetes business. The filing text provided contains no financial terms, share counts, or exchange ratios. Form 425 filings typically accompany a registration statement covering securities to be distributed or exchanged in the transaction. The filing signals that documentation for the MiniMed separation is progressing. The exchange offer terms and any resulting capital structure changes should be disclosed in the related registration statement or prospectus when finalized.

SEC 425•1mo ago

MDT: 425 · acquisition merger

Medtronic plc filed a Form 425 containing the text of a website maintained in connection with its offer to exchange up to an aggregate of 225,361,295 newly issued shares of MiniMed Group, Inc. common stock, which are owned by Medtronic, for shares of Medtronic common stock, as further described in the related prospectus. The offer is the split-off step of Medtronic's separation of its diabetes business, and the informational website is hosted by D.F. King at dfking.com/MDTSeparation. Medtronic shareholders who elect to exchange will receive MiniMed stock in return for their Medtronic shares, completing the separation and leaving remaining holders with a more focused Medtronic; this notice itself contains no exchange ratio, timeline, or financial terms.

SEC 425•1mo ago

MDT: 8-K · offering registration

Medtronic plc filed an 8-K on September 17, 2026 to correct a typographical error in the prospectus for the exchange offer it commenced on September 14, 2026, under which shareholders may tender Medtronic ordinary shares for up to 225,361,295 newly issued shares of MiniMed Group, Inc. common stock as part of the MiniMed separation. The correction clarifies the guaranteed delivery procedures: an executed notice of guaranteed delivery expires at 5:00 p.m. New York City time on the second NYSE trading day after execution, not at 12:00 midnight as originally printed in the prospectus. Medtronic also reiterated that if the exchange offer is oversubscribed, it currently intends to accept additional validly tendered shares not to exceed 2% of total outstanding Medtronic ordinary shares. D.F. King & Co. is serving as information agent, and the filing makes no change to the terms or economics of the offer itself.

SEC 8-K•1mo ago

MDT: 425 · acquisition merger

Medtronic plc filed a Rule 425 communication confirming it maintains a dedicated website (https://www.dfking.com/MDTSeparation) for its proposed separation of MiniMed Group, Inc. Through the offer, Medtronic is proposing to exchange up to an aggregate of 225,361,295 newly issued shares of MiniMed Group common stock, currently owned by Medtronic, for shares of Medtronic common stock — a split-off exchange-offer structure. The exchange ratio, expiration and conditions are set out in the referenced Prospectus and are not detailed in this filing excerpt, so investors should review the full prospectus before acting.

SEC 425•1mo ago

MDT: 425 · acquisition merger

Medtronic filed a Rule 425 communication containing exchange offer talking points prepared for Fidelity phone representatives who will handle ESPP participant elections tied to Medtronic's separation of MiniMed Group, Inc. Medtronic is offering its shareholders the opportunity to exchange some or all of their Medtronic ordinary shares for shares of MiniMed Group, Inc., a company being separated from Medtronic. Under the ESPP procedures, shares are eligible to be tendered only if held at least one year from the purchase date, while shares acquired through dividend reinvestment are exempt from the holding period. ESPP participants must submit and may withdraw their elections by October 8, 2026, which is earlier than the general offer deadlines, and MiniMed will not issue fractional shares — fractional entitlements will be aggregated and sold in the open market, with participants receiving their proportional share of net cash proceeds. The document is administrative support for an already-disclosed separation and contains no new deal terms or financial figures. The exchange offer is made solely by the Prospectus forming part of MiniMed's Form S-4 registration statement, Medtronic has filed a Schedule TO, and D.F. King & Co. is serving as information agent for shareholder questions.

SEC 425•1mo ago

MDT: 425 · acquisition merger

Medtronic has launched an exchange offer allowing its shareholders to exchange some or all of their Medtronic ordinary shares for MiniMed common stock, the final major step in the MiniMed separation. Once the offer and related transactions are complete, Medtronic will hold no equity stake in MiniMed, which will operate as a fully independent public company. MiniMed says it has crossed $3 billion in annual revenue in the roughly 18 months since the separation was announced, supported by its IPO earlier this year and the launches of MiniMed Flex and MiniMed Go automated insulin delivery products. Day-to-day operations are unchanged for now, with MiniMed continuing to execute under transition service agreements with Medtronic and preparing to onboard nearly 900 employees in Day 2 countries. The exchange offer is being made through MiniMed's Form S-4 prospectus and Medtronic's Schedule TO, with D.F. King & Co. serving as information agent.

SEC 425•1mo ago

MDT: 425 · acquisition merger

Medtronic has commenced an exchange offer allowing shareholders to swap Medtronic ordinary shares for newly issued MiniMed Group common stock, the final step in the divestiture of its Diabetes Operating Unit first announced on May 21, 2025. MiniMed completed its IPO on March 9, 2026, and Medtronic continues to own approximately 89.86% of MiniMed's outstanding shares; once the exchange offer and related transactions are completed, Medtronic will hold no equity stake and MiniMed will operate as an independent public company. The transaction is intended to qualify as tax-free under Section 355 of the Internal Revenue Code. Personally held Medtronic shares and ESPP shares that have met the one-year holding period are eligible for tender, while unvested RSUs, PSUs, and unexercised stock options are not; questions are directed to information agent D.F. King & Co., Inc.

SEC 425•1mo ago

MiniMed Files Form S-4 Registration Statement in Connection with Medtronic Exchange Offer Announcement

Medtronic's split-off of MiniMed entered its final stage as MiniMed filed a Form S-4 registration statement with the SEC covering Medtronic's exchange offer, under which MDT shareholders can exchange Medtronic ordinary shares for up to 225,361,295 MiniMed shares, or 80.1% of MiniMed's outstanding stock. Medtronic currently owns roughly 89.86% of MiniMed; if the offer is oversubscribed, Medtronic will exchange its remaining 27,452,053 MiniMed shares without extending the offer period, and once complete Medtronic will hold no equity stake in MiniMed. MiniMed CEO Que Dallara said the final-stage separation gives the company complete autonomy over its capital allocation, product roadmap, and speed, with execution entirely in its own hands.

•1mo ago

Teleflex Appoints Veteran Medical Technology Executive Sean M. Salmon to Teleflex Board of Directors

Teleflex Incorporated (NYSE: TFX) appointed medical technology veteran Sean M. Salmon to its Board of Directors, effective September 8, 2026, bringing the board to nine directors, eight of whom are independent. Salmon spent more than 20 years at Medtronic (NYSE: MDT), most recently as EVP and President of its Cardiovascular Portfolio, a global business with fiscal 2025 revenue of approximately $12.5 billion. He currently serves as an independent director of Adagio Medical Holdings (Nasdaq: ADGM), the filer of this card. He will also join Teleflex's Growth and Operating Committee, created earlier this year to support the company's strategic transformation; one third of the Teleflex board will have been refreshed in 2026. For ADGM, the release contains no new operational or financial disclosure -- its only relevance is director overlap, as Salmon remains an Adagio board member while taking on the Teleflex seat.

•1mo ago

For These Three Interns, The Medtronic Mission Is Personal

Medtronic highlighted the stories of three interns—Sofia Jalenak, Violet Oliver, and Melissa Hermosillo Nava—whose personal experiences with medical technology inspired them to join the company's Cardiac Rhythm Management, Cranial and Spinal Technologies, and Surgical Operating Unit teams. The article emphasizes the interns' use of AI in their respective roles to support device development and surgical tools, linking their personal patient journeys to their professional contributions. The release also serves as a recruitment announcement, noting that applications for the 2027 Summer Internship Program are open until October 15, 2026.

•2mo ago